1. Home
  2. SBFM vs IMRN Comparison

SBFM vs IMRN Comparison

Compare SBFM & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunshine Biopharma Inc.

SBFM

Sunshine Biopharma Inc.

HOLD

Current Price

$1.10

Market Cap

6.0M

Sector

Health Care

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.82

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBFM
IMRN
Founded
2006
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0M
6.2M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
SBFM
IMRN
Price
$1.10
$0.82
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
31.0K
19.1K
Earning Date
05-14-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.26
N/A
Revenue Next Year
$32.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.68
52 Week High
$2.43
$2.38

Technical Indicators

Market Signals
Indicator
SBFM
IMRN
Relative Strength Index (RSI) 42.78 52.49
Support Level N/A $0.69
Resistance Level $1.52 $0.89
Average True Range (ATR) 0.04 0.06
MACD 0.00 0.01
Stochastic Oscillator 26.77 53.87

Price Performance

Historical Comparison
SBFM
IMRN

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: